Results 221 to 230 of about 780,731 (377)

Concentration risk and the optimal number of central counterparties for a single asset [PDF]

open access: yes
We model the central counterparty (CCP) clearing of a single asset traded over-the-counter by two groups of banks in two currencies. We compare a variety of different clearing set-ups involving one or two CCPs according to their ability to withstand a ...
Renault, F.
core  

Chemical Landscape for Tissue Clearing Based on Hydrophilic Reagents.

open access: yesCell Reports, 2018
Kazuki Tainaka   +24 more
semanticscholar   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Rapid and efficient protocol for optical clearing of mouse intestinal tissues for enhanced fluorescence imaging and 3D reconstruction. [PDF]

open access: yesSTAR Protoc
George JJ   +11 more
europepmc   +1 more source

Antigen retrieval and clearing for whole-organ immunofluorescence by FLASH

open access: yesNature Protocols, 2020
H. Messal   +9 more
semanticscholar   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Home - About - Disclaimer - Privacy